請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39404
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林欽塘 | |
dc.contributor.author | Tong-Young Lee | en |
dc.contributor.author | 李冬陽 | zh_TW |
dc.date.accessioned | 2021-06-13T17:27:43Z | - |
dc.date.available | 2010-04-15 | |
dc.date.copyright | 2005-02-05 | |
dc.date.issued | 2004 | |
dc.date.submitted | 2004-11-25 | |
dc.identifier.citation | part1
1. Waterhouse, L., Muir, C., Shanmugaratnam, K., Powell, J., Peachham, D., and Whelan, S. (1982) Cancer incidence in five continents, International agency for research on cancer scientific publication 42, vol IV. Lyon, International agency for research on cancer 2. Armstrong, R. W., Armstrong, M. J., and Yu, C. M. (1983) Salted fish and inhalants as risk factor for nasopharyngeal carcinoma in Malaysian Chinese. Cancer Res., 43: 2967-2970 3. Ho, C. K., Lo, W. C. H., Huang, P. H., Wu, M. T., Christiani, D. C., and Lin, C. T. (1999) Suspected nasopharyngeal carcinoma in three workers with long-term exposure to sulfuric acid vapor. Occup. Environ. Med., 56: 426-428 4. Klein, G., Giovanella, B. C., Lindahl, T., Fialkow, P. J., Singh, S., and Stehlin, J. S. (1974) Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc. Natl. Acad. Sci. USA, 71: 4737-4741 5. Speth, P. A. J., Hoesel, Q. G. C. M., and Haanen, C. (1988) Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet., 15: 15-31 6. Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., and Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 51: 691-743 7. Gabizon, A., and Martin, F. (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Drugs, 54 (Suppl 4): 15-21 8. Martin, F. J. (1998) Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin), in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) p 635–688, Elsevier Science BV, New York 9. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464 10. Dvorak, H. F., Nagy, J. A., and Dvorak, A. M. (1991) Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77-85 11. Shockley, T. R., Lin, K., Nagy, J. A., Tompkins, R. G., Dvorak, H. F., and Yarmish, M. L. (1991) Penetration of tumor tissue by antibodies and other immunoproteins. Ann. NY Acad. Sci., 618: 367-382 12. Li, B., Tom, J. Y., Oare, D., Yen, R., Fairbrother, W. J., Wells, J. A., and Cunningham, B. C. (1995) Minimization of a polypeptide hormone. Science, 270: 1657-1660 13. Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., and Dower, W. J. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science, 273: 458-463 14. Young, A. C., Valadon, P., Casadevall, A., Scharff, M. D., and Sacchettini, J. C. (1997) The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implications for the identification of peptide mimotopes. J. Mol. Biol., 274: 622-634 15. Wu, H. C., Jung, M. Y., Chiu C. Y., Lai, S. C., Jan, J. T., and Shaio, M. F. (2003) Identification of serotype-specific B-cell epitope of dengue virus type 2 and detection of dengue immunized serum samples by epitope-based peptide antigen. J. Gen. Virol., 84: 2271-2279 16. Barry, M. A., Dower, W. J., and Johnston, S. A. (1996) Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med., 2: 299-305 17. Spear, M. A., Breakefield, X. O., Beltzer, J., Schuback, D., Weissleder, R., Pardo, F. S., and Ladner R. (2001) Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Therapy, 8: 506-511 18. Pasqualini, R., and Ruoslahti, E. (1996) Organ targeting in vivo using phage display peptide libraries. Nature, 380: 364-366 19. Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997) αν Integrins as receptors for tumor targeting by circulating ligands. Nature Biotechnol., 15: 542-546 20. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279: 377-380 21. Lin, C. T., Wong, C. I., Chan W. Y., Tzung, K. W., Ho, J. K. C., Hsu, M. M., and Chuang, S. M. (1990) Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab. Invest., 62: 713-724 22. Lin, C. T., Chan, W. Y., Chen, W., Huang, H. M., Wu, H. C., Hsu, M. M., Chuang, S. M., and Wang, C. C. (1993) Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab. Invest., 68: 716-727 23. Tseng, Y. L., Hong, R. L., Tao, M. H., and Chang, F. H. (1999) Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int. J. Cancer, 80: 723-730 24. Habeeb, A. F. S. A. (1966) Determination of free amino groups in protein by trinitrobenzene sulfuric acid. Anal. Biochem., 14: 328 25. Zalipsky, S., Mullah, N., Harding, J. A., Gittelman, J., Guo, L., and DeFrees, S. A. (1997) Poly (ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjugate Chemistry, 8: 111-118 26. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W., Carter, P., Benz, C. C., and Papahadjopoulos, D. (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer in vitro. Biochemistry, 36: 66-75 27. Sainsbury, J. R., Farndon, J. R., Needham, G. K., Malcolm, A. J., Harris, A. L. (1987) Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1: 1398-1402 28. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235: 177-182 29. Vingerhoeds, M. H., Steerenberg, P. A., Hendriks, J. J. G. W., Dekker, L. C., van Hoesel, Q. G. C. M., Crommelin, D. J. A., and Storm, G. (1996) Immunoliposome-mediated targeting of doxorubicin of human ovarian carcinoma in vitro and in vivo. Brit. J. Cancer, 74: 1023-1029 30. Park, J. W., Hong, K., Carter, P., Asgari, H., Guo, L. Y., Keller, G. A., Wirth, C., Shalaby, R., Kotts, C., and Wood, W. I. (1995) Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA, 92: 1327-1331 31. Haran, G., Cohen, R., Bar, L. K., and Barenholz, Y. (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta., 1151: 201-215 32. Essler, M., and Ruoslahti, E. (2002) Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. USA, 99: 2252-2257 33. McDonald D. and Baluk P. (2002) Significance of blood vessel leakiness in cancer. Cancer Res., 62: 5381-5385 34. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., and McDonald, D. M. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol., 160: 985–1000 35. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., and McDonald, D. M. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 156: 1363-1380 36. Matsumura, Y., and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 46: 6387-6392 37. Huang, S. K., Mayhew, E., Gilani, S., Lasic, D. D., Martin, F. J., and Papahadjopoulos, D. (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res., 52: 6774-6781 38. Jain, R. K. (1996) Delivery of molecular medicine to solid tumors. Science, 271: 1079-1080 39. Jain, R. K. (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res., 50 (3 Suppl): 814s-819s. part2 1. Minna, J. D., Gazder A. F., Sprang, S. R., and Herz, J. (2004) A bull’s eye for targeted lung cancer therapy. Science, 304: 1458-1461. 2. Berger, G., Song, S., Meyer-Morse, N., Folkman, J., and Hanahan, D. (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest., 111: 1287-1295. 3. Ruoslahti, E. (2002a) Drug targeting to specific vascular sites. Drug Discov. Today, 7: 1138-1143. 4. Ruoslahti, E. (2002b) Specialization of tumor vasculature. Nat. Rev. Cancer, 2: 83-90. 5. Eliceriri, B. P., and Cheresh, D. A. (1999) The role of alpha integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest., 103: 1127-1130. 6. Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997) αν Integrins as receptors for tumor targeting by circulating ligands. Nature Biotechnol., 15: 542-546. 7. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279: 377-380. 8. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60:722-727. 9. Burg, M. A., Pasqualini, R., Arap, W., Ruoslahti, E., and Stallcup, W. B. (1999) NG2 proteoglycan-binding peptides target tumor vasculature. Cancer Res., 59: 2869-2874. 10. Ozerden, U. et al., (2001) NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn., 222: 218-227. 11. Speth, P. A. J., Hoesel, Q. G. C. M., and Haanen, C. (1988) Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet., 15: 15-31. 12. Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., and Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev., 51: 691-743. 13. Gabizon, A., and Martin, F. (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Drugs, 54 (Suppl 4): 15-21. 14. Martin, F. J. (1998) Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin), in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) p 635–688, Elsevier Science BV, New York. 15. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464. 16. Dvorak, H. F., Nagy, J. A., and Dvorak, A. M. (1991) Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77-85. 17. Shockley, T. R., Lin, K., Nagy, J. A., Tompkins, R. G., Dvorak, H. F., and Yarmish, M. L. (1991) Penetration of tumor tissue by antibodies and other immunoproteins. Ann. NY Acad. Sci., 618: 367-382. 18. Li, B., Tom, J. Y., Oare, D., Yen, R., Fairbrother, W. J., Wells, J. A., and Cunningham, B. C. (1995) Minimization of a polypeptide hormone. Science, 270: 1657-1660. 19. Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., and Dower, W. J. (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science, 273: 458-463. 20. Wu, H. C., Jung, M. Y., Chiu C. Y., Lai, S. C., Jan, J. T., and Shaio, M. F. (2003) Identification of serotype-specific B-cell epitope of dengue virus type 2 and detection of dengue immunized serum samples by epitope-based peptide antigen. J. Gen. Virol., 84: 2271-2279. 21. Lee, T. Y., Wu, H. C., Tseng, Y. L., and Lin, C. T. (2004) A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res., 64: 8002-8008. 22. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279: 377-380. 23. Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G.., Ruoslahti, E., and Hanahan, D. (2003) Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4: 393-403. 24. Liu, I. J., Hsueh, P. R. Lin, C. T., Chiu, C. Y., Kao, C. L., Liao, M. Y. and Wu, H. C. (2004) Disease-specific B cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. J. Infect. Dis. 190: 797-809. 25. Wu, H. C, Huang, Y. L., Chao T. T., Jan, J. T., Huang, J. L., Chiang H Y., King C. C., and Shaio, M. F. (2001) Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. J. Clin. Microbiol., 39: 977-982. 26. Wu, H. C., Jung, M. Y., Chiu C. Y., Lai, S. C., Jan, J. T., and Shaio, M. F. (2003) Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J. Gen. Virol., 84: 2271-2279. 27. Wu, H. C., Yeh, C. T., Huang, Y. L., Tarn, L. J., and Lung, C. C. (2001) Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A. Appl. Environ. Microbiol., 67: 3201-3207. 28. Barry, M. A., Dower, W. J., and Johnston, S. A. (1996) Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat. Med., 2: 299-305. 29. Pasqualini, R., and Ruoslahti, E. (1996) Organ targeting in vivo using phage display peptide libraries. Nature, 380: 364-366. 30. Chu, Y. W., Yang, P. C., Yang, S. C., Shyu, Y. C., Hendrix, M. J., Wu, R., et al. (1997) Selection of invasion and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol ., 17: 353–60. 31. Lin, C. T., Wong, C. I., Chan W. Y., Tzung, K. W., Ho, J. K. C., Hsu, M. M., and Chuang, S. M. (1990) Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab. Invest., 62: 713-724 32. Tseng, Y. L., Hong, R. L., Tao, M. H., and Chang, F. H. (1999) Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int. J. Cancer, 80: 723-730. 33. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U. B., Marks, J. D., Moore, D., Papahadjopoulos, D., and Benz, C. C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clinical Cancer Res. 8: 1172-1181, 2002. 34. Oku, N., Asai, T., Watanabe, K., Kuromi, K., Nagatsuka, M., Kurohane, K., Kikkawa, H., Ogino, K., Tanaka, M., Ishikawa, D., Tsukada, H., Momose, M., Nakayama, J., and Taki, T. (2002) Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene, 21: 2662-2669. 35. Hoffman, J. A., Giraudo, E., Singh, M., Zhang L., Inoue, M., Porkka, K., Hanahan, D., and Ruoslahti, E. (2003) Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell, 4: 383-391. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/39404 | - |
dc.description.abstract | 一
對於住在南中國、台灣及新加坡的人來說,鼻咽癌(Nasopharyngeal carcinoma, NPC)是一種極為常見的癌症。對鼻咽癌病人進行化療常有不小的副作用,然而專一性的標的療法或許可以解決此一問題。利用phage display的方法我們找到一種鼻咽癌細胞的標的胜肽。此一標的胜肽具有與鼻咽癌細胞及鼻咽癌病人檢體專一性結合的能力,同時也可以和在異體移植的鼻咽癌腫瘤細胞有專一性的結合。當與化學治療藥物連結後,其可用於引導化學治療藥物至腫瘤細胞,將腫瘤細胞殺死,而不致因施予化學治療藥物而傷害到其他正常組織及器官。又此一標的胜肽可專一性的與鼻咽癌細胞結合,因此該標的胜肽亦可被應用於作為開發鼻咽癌檢驗試劑用。 二 惡性腫瘤目前不僅在台灣或是全世界已成為一個非常嚴重的公共衛生問題。利用化療方式來治療腫瘤,仍然存在抗藥性及專一性辨認的問題。癌症的標的治療或許可以解決此一問題。我們利用動物活體噬菌體顯現法來尋找針對異體移殖腫瘤血管有專一性結合之胜肽(S5-52 and L4-2)。S5-52 及 L4-2胜肽表現之噬菌體及FITC標記之S5-52 及 L4-2胜肽均可和肺癌細胞株PC13異體移植腫瘤之血管內皮細胞結合,另外在S5-52胜肽表現之噬菌體亦可和喉癌(HEp-2)、口腔癌(SAS)、肺癌(CL1-5)等細胞株之異體移殖腫瘤之血管內皮細胞結合而不與正常組織的血管內皮細胞結合。當此一標記胜肽S5-52與微脂體包裹之化療藥物連結後,可用於引導化療藥物至腫瘤組織,將血管破壞並可殺死腫瘤細胞,而不傷害到其他正常組織及器官。此一標記胜肽S5-52未來極有潛力被應用於作為開發腫瘤之標的治療。 | zh_TW |
dc.description.abstract | 1.
Nasopharyngeal carcinoma (NPC) is a common cancer among Chinese living in South China, Taiwan and Singapore. For treatment of NPC by chemotherapy, most cancer chemotherapeutics lack selectivity for cancer cells. Ligand-targeted therapy could afford tumor specificity and limitless toxicity for normal tissue. In this study, we identified a 12-mer peptide (L-peptide) specifically binding to NPC cells by phage display peptide libraries. In vitro, the L-peptide bound to the cell surfaces of most NPC cell lines and biopsy specimens; the L-peptide-linked fluorescence containing liposome was capable of binding to and translocation across plasma membranes. Similarly, the L-peptide-linked liposome that carried doxorubicin (L-peptide-Lipo-Dox) could cause marked NPC cytotoxicity. In vivo, in SCID mice bearing NPC xenograft, the L-phages could specifically bind to the tumor mass; in addition, the L-peptide-Lipo-Dox had higher efficacy to inhibit tumor growth than Lipo-Dox. These results indicate that the L-peptide is a novel peptide, which can specifically bind to NPC cells, and is a good candidate for targeted drug delivery to NPC solid tumors. 2. Malignant tumor has emerged as a major public health problem in developing countries, Taiwan and other parts of world. For treatment of advance tumor by chemotherapy, most cancer chemotherapeutics lack selectivity for cancer cells. Ligand-targeted therapy could afford tumor specificity and limited toxicity for normal tissue. In this study, we identified the 12-mer peptides specifically binding to the neovasculature of SCID mice bearing lung adenocarcinoma xenograft (PC13) by in vivo phage display. We have identified S5-52 and L4-2-phages could bind to the endothelial cells of PC13 xenograft tumors. The FITC-labeled S5-52 peptide and S5-52-phage treated SCID mice also showed the specific binding to neovasculature of xenograft tumors derived from laryngeal cancer (HEp-2), oral cancer (SAS), and lung cancer (CL1-5). The S5-52 peptide could also bind to human umbilical vein endothelial cells (HUVECs). The S5-52 peptide-linked liposome that carried doxorubicin had higher efficacy than Lipo-Dox in inhibit tumor growth without side effect. These results indicate that the S5-52-peptide is a novel peptide, which can specifically bind to neovasculature in xenograft tumors, and is a good candidate for targeted drug delivery to solid tumors. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T17:27:43Z (GMT). No. of bitstreams: 1 ntu-93-D88444001-1.pdf: 1316418 bytes, checksum: f495886d88a2b2647094070915d83676 (MD5) Previous issue date: 2004 | en |
dc.description.tableofcontents | Contents (PART 1)
中文摘要 1 ABSTRACT 2 INTRODUCTION 3 EXPERIMENTAL PROCEDURES 7 RESULTS 21 DISCUSSION 28 REFERENCES 37 FIGURES and TABLES 44 Contents (PART 2) 中文摘要 1 ABSTRACT 2 INTRODUCTION 3 EXPERIMENTAL PROCEDURES 8 RESULTS 15 DISCUSSION 19 REFERENCES 23 FIGURES and TABLES 28 APPENDIX | |
dc.language.iso | en | |
dc.title | 腫瘤標的胜肽之研發及其在化療之應用 | zh_TW |
dc.title | Development of the novel tumor-homing peptides for drug delivery and application in chemotherapy
1. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery 2. The tumor-homing peptides with targeting specificity related to tumor blood vessels and for drug delivery | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 吳漢忠 | |
dc.contributor.oralexamcommittee | 黃德富,蕭水銀,郭明良,徐明達,楊文光,蘇燦隆,陳鈴津 | |
dc.subject.keyword | 腫瘤標的胜肽,鼻咽癌, | zh_TW |
dc.subject.keyword | tumor-homing peptides,NPC, | en |
dc.relation.page | 99 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2004-11-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-93-1.pdf 目前未授權公開取用 | 1.29 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。